首页> 外文期刊>American Journal of Cancer Research >Overall survival, locoregional recurrence, and distant metastasis of definitive concurrent chemoradiotherapy for cervical squamous cell carcinoma and adenocarcinoma: before and after propensity score matching analysis of a cohort study
【24h】

Overall survival, locoregional recurrence, and distant metastasis of definitive concurrent chemoradiotherapy for cervical squamous cell carcinoma and adenocarcinoma: before and after propensity score matching analysis of a cohort study

机译:用于宫颈鳞状细胞癌和腺癌的明确同时化疗的总体存活,招生复发和远端转移:在群组研究之前和之后的倾向分数匹配分析

获取原文
           

摘要

Purpose: To estimate the outcomes of definitive concurrent chemoradiotherapy (CCRT) for bulky or advanced-stage cervical squamous cell carcinoma (SCC) and adenocarcinoma (ADC). Patients and methods: We enrolled patients who had been diagnosed as having cervical SCC or ADC and received definitive CCRT. A Cox regression analysis was performed to determine the hazard ratio (HR) and 95% confidence intervals (95% CI); independent predictors were stratified or controlled for in the analysis, and the endpoint was all-cause mortality among patients with cervical SCC and ADC who received CCRT. Propensity score matching was performed to create well-balanced groups. Results: we enrolled 3258 patients who had International Federation of Gynecology and Obstetrics (FIGO) stage IB2-IVA cervical cancer without distant metastasis. Among them, 2927 patients with cervical SCC and 331 patients with cervical ADC received definitive CCRT. The results of multivariate Cox regression analysis indicated that ADC, advanced FIGO stage, no intracavitary brachytherapy, old age, earlier year of diagnosis, and higher comorbidity scores were significant independent poor prognostic factors of all-cause mortality in patients with cervical cancer who received definitive CCRT. Patients with cervical ADC who received definitive CCRT had higher all-cause mortality, locoregional recurrence (LRR), and distant metastasis (DM) (adjusted HR [95% CI]: 2.10 [1.79-2.46], 1.79 [1.35-2.37], and 1.97 [1.54-2.53] for all-cause mortality, LRR, and DM, respectively) compared with patients with cervical SCC who received CCRT. Conclusion: Definitive CCRT in patients with cervical ADC resulted in lower overall survival, higher LRR, and higher DM rate compared with patients with cervical SCC.
机译:目的:估算笨重或晚期宫颈细胞癌(SCC)和腺癌(ADC)的明确同时化学疗法(CCRT)的结果。患者和方法:我们注册患者被诊断为具有宫颈SCC或ADC并接受过明确的CCRT。进行COX回归分析以确定危害比(HR)和95%置信区间(95%CI);在分析中分层或控制独立的预测因子,并且终点是宫颈SCC和接受CCRT的ADC患者的所有导致死亡率。倾向进行分数匹配以创建均衡的群体。结果:我们注册了3258名患有国际妇科和妇产科(FICO)第IB2-IVA宫颈癌的国际联合会,没有远处转移。其中,2927例宫颈SCC和331例宫颈ADC患者接受了最终的CCRT。多元COX回归分析结果表明,ADC,先进的FIGO阶段,没有颈椎近距离放射治疗,晚年,诊断早期,和更高的合并症评分是宫颈癌患者的所有导致死亡率的显着独立差的预后因素,他们接受了最终的宫颈癌ccrt。接受过敏性CCRT的宫颈ADC患者具有更高的全因死亡率,型招生复发(LRR)和远处转移(DM)(调整后的HR [95%CI]:2.10 [1.79-2.46],1.79 [1.35-2.37],与接受CCRT的宫颈SCC患者相比,对全因死亡率,LRR和DM进行了1.97 [1.54-2.53]。结论:与宫颈SCC患者相比,宫颈ADC患者中的最终CCRT导致总存活率较低,LRR较高,DM率较高。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号